Seres Therapeutics, Inc. (MCRB)
NASDAQ$0.6886+0.05 (7.83%)
Market Cap
$111.15M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
699 of 924
Rank in Industry
399 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
MCRB Insider Trading Activity
MCRB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $82,340 | 28 | 100 |
Related Transactions
| Ege David S. | See Remarks | 0 | $0 | 2 | $1,972 | $-1,972 |
| Henn Matthew R. | See Remarks | 0 | $0 | 5 | $8,067 | $-8,067 |
| DesRosier Thomas | Chief Legal Officer and EVP | 0 | $0 | 5 | $8,425 | $-8,425 |
| von Moltke Lisa | See Remarks | 0 | $0 | 5 | $8,799 | $-8,799 |
| Shaff Eric D. | CEO and President | 0 | $0 | 5 | $22,110 | $-22,110 |
| Young Teresa L. | See Remarks | 0 | $0 | 6 | $32,967 | $-32,967 |
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal …
Insider Activity of Seres Therapeutics, Inc.
Over the last 12 months, insiders at Seres Therapeutics, Inc. have bought $0 and sold $82,340 worth of Seres Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Seres Therapeutics, Inc. have bought $9.18M and sold $681,788 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,912,748 shares for transaction amount of $9.18M was made by AFEYAN NOUBAR () on 2022‑07‑05.
List of Insider Buy and Sell Transactions, Seres Therapeutics, Inc.
| 2025-02-18 | Sale | Shaff Eric D. | CEO and President | 12,726 0.0073% | $0.81 | $10,314 | -11.70% | |
| 2025-02-18 | Sale | DesRosier Thomas | Chief Legal Officer and EVP | 4,300 0.0025% | $0.81 | $3,485 | -11.70% | |
| 2025-02-18 | Sale | Young Teresa L. | See Remarks | 3,338 0.0019% | $0.81 | $2,704 | -11.70% | |
| 2025-02-18 | Sale | Henn Matthew R. | See Remarks | 3,953 0.0023% | $0.81 | $3,204 | -11.70% | |
| 2025-02-18 | Sale | von Moltke Lisa | See Remarks | 4,416 0.0025% | $0.81 | $3,579 | -11.70% | |
| 2024-11-18 | Sale | Shaff Eric D. | CEO and President | 2,505 0.0014% | $0.54 | $1,355 | +43.50% | |
| 2024-11-18 | Sale | DesRosier Thomas | Chief Legal Officer and EVP | 878 0.0005% | $0.54 | $475 | +43.50% | |
| 2024-11-18 | Sale | Young Teresa L. | See Remarks | 735 0.0004% | $0.54 | $398 | +43.50% | |
| 2024-11-18 | Sale | Henn Matthew R. | See Remarks | 927 0.0005% | $0.54 | $501 | +43.50% | |
| 2024-11-18 | Sale | von Moltke Lisa | See Remarks | 977 0.0005% | $0.54 | $528 | +43.50% | |
| 2024-10-28 | Sale | Shaff Eric D. | CEO and President | 8,748 0.0045% | $0.69 | $6,037 | +16.33% | |
| 2024-10-28 | Sale | DesRosier Thomas | Chief Legal Officer and EVP | 4,259 0.0022% | $0.69 | $2,939 | +16.33% | |
| 2024-10-28 | Sale | Young Teresa L. | See Remarks | 2,983 0.0015% | $0.69 | $2,059 | +16.33% | |
| 2024-10-28 | Sale | Henn Matthew R. | See Remarks | 3,984 0.0021% | $0.69 | $2,749 | +16.33% | |
| 2024-10-28 | Sale | von Moltke Lisa | See Remarks | 4,334 0.0022% | $0.69 | $2,991 | +16.33% | |
| 2024-08-16 | Sale | Shaff Eric D. | CEO and President | 2,518 0.0015% | $0.84 | $2,115 | -5.62% | |
| 2024-08-16 | Sale | DesRosier Thomas | Chief Legal Officer and EVP | 873 0.0005% | $0.84 | $733 | -5.62% | |
| 2024-08-16 | Sale | Young Teresa L. | See Remarks | 728 0.0004% | $0.84 | $612 | -5.62% | |
| 2024-08-16 | Sale | Ege David S. | See Remarks | 1,128 0.0007% | $0.84 | $948 | -5.62% | |
| 2024-08-16 | Sale | Henn Matthew R. | See Remarks | 923 0.0006% | $0.84 | $775 | -5.62% |
Total: 118
*Gray background shows transactions not older than one year
Insider Historical Profitability
40%
| AFEYAN NOUBAR | 5875711 3.3748% | $3.75M | 2 | 1 | +40% |
Historical Insider Profitability vs. Competitors
$12,784,645 | 193 | 20.49% | $110.08M | |
$22,597,521 | 91 | 4.59% | $109.66M | |
$54,751,750 | 62 | -1.03% | $114.62M | |
$16,245,616 | 40 | 123.58% | $117.65M | |
$909,129 | 37 | 42.19% | $122.85M |
MCRB Institutional Investors: Active Positions
| Increased Positions | 27 | +28.42% | 4M | +5.55% |
| Decreased Positions | 35 | -36.84% | 4M | -6.13% |
| New Positions | 9 | New | 109,247 | New |
| Sold Out Positions | 18 | Sold Out | 675,378 | Sold Out |
| Total Postitions | 87 | -8.42% | 63M | -0.58% |
MCRB Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Flagship Pioneering Inc. | $17,546.00 | 13.52% | 23.12M | 0 | 0% | 2024-12-31 |
| Fmr Llc | $16,555.00 | 12.76% | 21.81M | -1M | -4.57% | 2024-12-31 |
| Vanguard Group Inc | $4,458.00 | 3.44% | 5.87M | -186,648 | -3.08% | 2024-12-31 |
| Morgan Stanley | $1,528.00 | 1.18% | 2.01M | +1M | +150.93% | 2024-12-31 |
| Millennium Management Llc | $1,374.00 | 1.06% | 1.81M | +788,762 | +77.18% | 2024-12-31 |
| Blackrock, Inc. | $1,337.00 | 1.03% | 1.76M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $1,146.00 | 0.88% | 1.51M | +121,793 | +8.77% | 2024-12-31 |
| Vontobel Holding Ltd. | $712.00 | 0.55% | 938,295 | +543,469 | +137.65% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $657.00 | 0.51% | 865,825 | +117,107 | +15.64% | 2024-12-31 |
| State Street Corp | $380.00 | 0.29% | 500,748 | +117,500 | +30.66% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.